Drug
Ruzasvir clinical trials
Also written MK-8408.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Merck Sharp & Dohme LLC (6) · Atea Pharmaceuticals, Inc. (2)
Often tested with
Tested in the same studies.
Uprifosbuvir (5) · Bemnifosbuvir (2) · Grazoprevir (2) · Elbasvir (2) · AT-511 (1) · Ribavirin (1) · MK-3682B (1)
Studies
Open first, then newest update. How each study uses ruzasvir is read from its arms, and is right about nine times in ten.
Testing it · 8
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)CompletedPhase 1Atea Pharmaceuticals, Inc.NCT07272889Written as Bemnifosbuvir/Ruzasvir (BEM/RZR)
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVCompletedPhase 2Atea Pharmaceuticals, Inc.NCT05904470Written as Ruzasvir
- Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02956629Written as Ruzasvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332720Written as Ruzasvir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Ruzasvir
- Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02759315Written as Ruzasvir 60 mg
- Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT02076100Written as Ruzasvir
- A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)CompletedPhase 1Merck Sharp & Dohme LLCNCT02666352Written as Ruzasvir
Codes
What other systems call ruzasvir · ClinicalTrials.gg INT000748
- MeSH (NLM) C000621654ruzasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LX752BD95YRUZASVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27283234ruzasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152277RuzasvirOne source FDA
- DrugBank DB11713One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621654 | ruzasvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LX752BD95Y | RUZASVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27283234 | ruzasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152277 | Ruzasvir | One source FDA |
| DrugBank | DB11713 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.